Eliem Therapeutics Share Holder Equity 2021-2024 | CLYM
Eliem Therapeutics share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Eliem Therapeutics Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$108 |
| 2022 |
$129 |
| 2021 |
$167 |
| 2020 |
$-25 |
Eliem Therapeutics Quarterly Share Holder Equity
(Millions of US $) |
| 2024-06-30 |
$222 |
| 2024-03-31 |
$106 |
| 2023-12-31 |
$108 |
| 2023-09-30 |
$110 |
| 2023-06-30 |
$113 |
| 2023-03-31 |
$117 |
| 2022-12-31 |
$129 |
| 2022-09-30 |
$134 |
| 2022-06-30 |
$142 |
| 2022-03-31 |
$155 |
| 2021-12-31 |
$167 |
| 2021-09-30 |
$177 |
| 2021-06-30 |
$-51 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
|
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
